Phase 2a study of ZGN-1061 in patients with type 2 diabetes who are overweight or obese
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs ZGN 1061 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 08 Aug 2017 According to a Zafgen media release, this trial is expected to begin in the third quarter of 2017.
- 09 May 2017 According to a Zafgen media release, data from this trial expected by the end of 2018.
- 09 May 2017 According to a Zafgen media release, based on the data from a Phase I trial (see profile 274521) along with non-clinical data supporting a differentiated profile and improved safety margin versus first generation MetAP2 inhibitors, the Company plans to initiate this trial.